| P50 | author | Jaime A Espinoza | Q57002387 |
| | Irina Gromova | Q58413864 |
| | Vera Timmermans Wielenga | Q41607425 |
| | Maj-Lis Møller Talman | Q41608063 |
| P2093 | author name string | Niels Kroman | |
| | Pavel Gromov | |
| | José M A Moreira | |
| | Naoko Honma | |
| P2860 | cites work | The human fatty acid-binding protein family: evolutionary divergences and functions | Q21245453 |
| | Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma | Q24548280 |
| | High resolution two-dimensional electrophoresis of proteins | Q24608190 |
| | Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels | Q27860531 |
| | Molecular portraits of human breast tumours | Q28032461 |
| | Global quantification of mammalian gene expression control | Q28238103 |
| | Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family | Q28258227 |
| | Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast | Q28265668 |
| | Molecular characterization of breast cancer cell lines by a low-density microarray | Q28270635 |
| | FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status | Q28297008 |
| | TM4 microarray software suite | Q29618829 |
| | Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. | Q33739841 |
| | Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? | Q33932665 |
| | Ketone body utilization drives tumor growth and metastasis | Q34307146 |
| | A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer | Q34551559 |
| | Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. | Q34977042 |
| | Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study | Q35083868 |
| | Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options | Q35088745 |
| | Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 |
| | Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. | Q35176984 |
| | Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies | Q35573116 |
| | A refined molecular taxonomy of breast cancer | Q35838290 |
| | New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours | Q35889554 |
| | Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition | Q35969019 |
| | Androgen receptor as a targeted therapy for breast cancer. | Q36135807 |
| | The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. | Q51096608 |
| | Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma. | Q51750335 |
| | Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. | Q54630457 |
| | Hormone receptor profile of apocrine lesions of the breast. | Q54656221 |
| | Alterations of the cell cycle regulators cyclin D1, cyclin A, p27, p21, p16, and pRb in apocrine metaplasia of the breast. | Q54731196 |
| | Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors | Q77950099 |
| | Expression of oestrogen receptor-beta in apocrine carcinomas of the breast | Q80191342 |
| | Apocrine carcinomas of the breast | Q81368880 |
| | 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? | Q81368884 |
| | EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast | Q83147969 |
| | Non-operative breast pathology: apocrine lesions | Q36172494 |
| | A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis | Q36423097 |
| | Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells | Q36426491 |
| | Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. | Q36456638 |
| | Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer | Q36596837 |
| | Insights into the regulation of protein abundance from proteomic and transcriptomic analyses | Q36846022 |
| | An update on apocrine lesions of the breast | Q37048752 |
| | A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma | Q37213095 |
| | More than just a cargo adapter, melanophilin prolongs and slows processive runs of myosin Va | Q37226089 |
| | Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease | Q37734257 |
| | 2D gels still have a niche in proteomics. | Q38077011 |
| | Apocrine carcinoma of the breast: a comprehensive review | Q38114820 |
| | Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. | Q38451314 |
| | Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer | Q38491456 |
| | A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. | Q38526448 |
| | A single lysis solution for the analysis of tissue samples by different proteomic technologies | Q39985766 |
| | An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen | Q40313659 |
| | Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. | Q40472812 |
| | Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. | Q40685834 |
| | Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort | Q41130064 |
| | Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast | Q41130687 |
| | Keratin 19 expression in the adult and developing human mammary gland | Q41138370 |
| | Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia | Q41251750 |
| | Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer | Q42045155 |
| | 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. | Q42439006 |
| | The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. | Q42456749 |
| | Overexpression of fatty acid binding protein-7 correlates with basal-like subtype of breast cancer | Q42457015 |
| | Identification of molecular apocrine breast tumours by microarray analysis. | Q42478400 |
| | Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma | Q42504088 |
| | Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer | Q42505879 |
| | Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation | Q43246075 |
| | Immunohistochemically defined subtypes and outcome of apocrine breast cancer | Q44020922 |
| | Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast | Q46620153 |
| | Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients | Q46773052 |
| | Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. | Q46827099 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e112024 | |
| P577 | publication date | 2014-11-12 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast. | |
| P478 | volume | 9 | |